Therefore, the first‐line treatment options for HER2‐altered lung adenocarcinoma remain the same as those for oncogene wild‐type patients, using platinum‐based doublet chemotherapy in combination with immune checkpoint inhibitors (ICIs) and/or bevacizumab. The gene discussed is ERBB2; the disease is lung adenocarcinoma.